Shire drops drug’s new use after phase three disappointment
Shire’s ADHD drug lisdexamfetamine (Vyvanse) failed to meet endpoints in two phase three trials evaluating a new role in depression.
The “disappointment” has led the company to decide to drop further investigation for the extended indication.
Shire ends research into Vyvanese’s use in depression (The Wall Street Journal).
Shire reports top-line results from two phase 3 studies for Vyvanse (lisdexamfetamine dimesylate) capsules (CII) as an adjunctive treatment for adults with major depressive disorder (Shire press release).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.